HOME >> MEDICINE >> NEWS
Testosterone gel (AndroGel(R)) study first to show long-term benefits and safety

Torrance, Calif. (May 4, 2004) Long-term use of AndroGel (testosterone gel 1% CIII) is safe and effective for men with hypogonadism, a condition sometimes referred to as low testosterone, according to a new study published today in the May issue of the Journal of Clinical Endocrinology & Metabolism. The study, the first to examine safety and efficacy of testosterone gel up to 42 months, was conducted at multiple research centers in the U.S. under the direction of investigators at the Research and Education Institute (REI) at Harbor-UCLA Medical Center. Dr. Christina Wang was the lead author.

With continuous AndroGel treatment, men in the study experienced rapid and sustained improvements in sexual function and mood. Decreases in fat mass and increases in lean body mass were persistent with treatment. Additionally, gradual and progressive increases in bone mineral density were seen in the spine and hip.

"This AndroGel study is the first to show long-term benefits and safety with testosterone gel that's great news for men suffering from low testosterone," said Ronald Swerdloff, MD, REI Investigator in the Division of Endocrinology, Metabolism & Nutrition, Harbor-UCLA General Clinical Research Center. "This study shows 3+ years of continued benefits and provides new information on the degree of safety for men treated with testosterone. Nevertheless, doctors must monitor their patients throughout therapy."

It is estimated that four to five million American men have low testosterone. It also is estimated that low testosterone affects about one in 10 men between the ages of 40 and 60 and more than two in 10 men over the age of 60. Studies show that men lose testosterone at a rate of approximately 10 percent each decade after age 30. Symptoms of low testosterone include diminished interest in sex, erectile dysfunction (ED), reduced lean body mass, decreased bone mineral density, depressed mood and fatigue.

Researchers stu
'"/>

Contact: David Feuerherd
df@issuesmangement.com
310-215-0234
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
4-May-2004


Page: 1 2 3

Related medicine news :

1. Testosterone supplements for elderly men
2. Testosterone deficiency found in one-third of diabetic men
3. Testosterone patch will test FDAs decision making
4. Testosterone improves womens sex lives
5. OHSU study: Testosterone deprivation makes men forget
6. Testosterone may help in recovery from strokes, suggests preliminary findings in study
7. Testosterone replacement improves muscle strength, function in HIV-infected women
8. Testosterone may reduce risk of stroke in men; Estrogen levels not related to stroke
9. Testosterone aids older mens brains, UCSF study says
10. Testosterone in women?
11. Testosterone skin patch improves sexual functioning in surgically menopausal women

Post Your Comments:
(Date:5/22/2013)... May 22, 2013 Spinal Elements, ... corporate headquarters in Carlsbad to 3115 Melrose Drive, ... from the company’s continued and projected growth and ... 8,500 square feet to over 40,000 square feet. ... Spinal Elements, indicated, “Our investment in these state-of-the-art ...
(Date:5/22/2013)... Lawrenceville, NJ and Los Angeles, CA (PRWEB) May 22, ... chairman of the board, The J. M. Smucker Company, ... GS1 Lifetime Achievement Awards yesterday at the GS1 General ... Los Angeles, California. Mr. Smucker and Mr. Wegman were ... adoption of GS1 Standards - the most broadly used ...
(Date:5/22/2013)... News) -- Children who are physically, sexually or emotionally ... later in life, a new review suggests. British ... likely to be obese as adults. They concluded that ... factor for obesity. "We found that being maltreated ... in adult life," study author Dr. Andrea Danese, a ...
(Date:5/22/2013)... cancer. However, when existing drugs boost p53, only a few tumors ... the journal Cell Reports shows how: tumors that live ... protein p21 than the protein PUMA; tumors that die have more ... shows a handful of genes that control this ratio. , "The ... Tumors turn it off and then they can avoid controls that ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine . , The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
Breaking Medicine News(10 mins):Health News:Spinal Elements®, Inc. Relocates Corporate Headquarters in Carlsbad 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Abused Children at Risk for Obesity as Adults: Study 2Health News:Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
(Date:5/22/2013)... 2013  Grifols, ein globales Unternehmen der ... , Spanien, präsentierte die Ergebnisse einer ... von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des ... ein Niveau anhebt, das innerhalb des für ... ist eine lebensbedrohliche, genetische Erkrankung, bei der ...
(Date:5/22/2013)... May 22, 2013 Varian Medical Systems ... received 510(k) clearance from the U.S. Food and ... processing workstation that combines radio frequency (RF) and ... Nexus DRF Digital X-Ray Imaging System™ has the ... receptors, including CCD cameras and commercially available flat-panel ...
(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces ... Pharmaceutical Guidebook Series (4) 2013 Edition Material and ... Imported Drug Registration: A Guidebook of Registration Application ... " to its online database. The ... medicines are always regarded by occidental as mysterious ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5
Cached News: